At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORIC Oric Pharmaceuticals Inc.
Trading 02-06 12:19:38 EST
10.51
+0.55
+5.52%
High10.66Low9.99Vol819.66K
Open10.36D1 Closing9.96Amplitude6.73%
Mkt Cap1.02BTradable Cap637.53MTotal Shares97.39M
T/O8.44MT/O Rate1.35%Tradable Shares60.66M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  02-06 05:01
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares
Reuters  ·  01-21
Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares
ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating
TIPRANKS  ·  01-15
ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating
Wedbush Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
TIPRANKS  ·  01-13
Wedbush Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Dow Jones  ·  01-13
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Oric Pharmaceuticals Raises $244 Million in Private Placement
Reuters  ·  01-12
Oric Pharmaceuticals Raises $244 Million in Private Placement
Oric Pharmaceuticals Appoints Kevin Brodbeck as Chief Technical Officer
Reuters  ·  01-12
Oric Pharmaceuticals Appoints Kevin Brodbeck as Chief Technical Officer
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
GlobeNewswire  ·  01-12
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Oric Pharmaceuticals Initiated at Overweight by Piper Sandler
Dow Jones  ·  01-07
Oric Pharmaceuticals Initiated at Overweight by Piper Sandler
Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target
MT Newswires Live  ·  01-07
Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  01-07
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
BUZZ-India's Orient Technologies rises after shareholders approve bonus issue
Reuters  ·  2025-12-30
BUZZ-India's Orient Technologies rises after shareholders approve bonus issue
Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk
Dow Jones  ·  2025-12-17
Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk
ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data
Simply Wall St.  ·  2025-12-09
ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Dow Jones  ·  2025-12-08
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees
Reuters  ·  2025-12-06
Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  2025-12-06
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  2025-12-06
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations
Reuters  ·  2025-12-05
Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
GlobeNewswire  ·  2025-12-05
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Introduction

Company Name.
Oric Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Issue price:
--